DCLK1 and colorectal cancer: Moreover, a KRAS synthetic lethal screening previously identified the related kinase DCLK2 as a hit in the colorectal DLD-1 cell line (52), suggesting DCLK1 as a potential target for combination therapy in the context of KRAS-mutated colorectal cancer.